Context and biological diversity
Cutaneous, mucosal and uveal melanomas do not form a biologically uniform group. In cutaneous tumors, features such as thickness, ulceration and disease extent help describe the population. A primary tumor sample and a metastasis sampled after treatment may represent different points in evolution.
What research makes it possible to study
TCGA organized cutaneous melanomas into groups with BRAF, RAS or NF1 alterations or without these dominant alterations. In that cohort, immune-response-related expression signals were also associated with outcome. An observational microenvironment association does not establish individual response to immunotherapy.
Application in a research project
Response research can integrate tumor and immune characteristics but should separate discovery from validation. Recording biopsy site, treatment exposure and time between sampling and intervention is useful. Resistance assessment requires longitudinal samples or appropriate comparisons; a single profile after progression cannot independently identify the cause of resistance.
Research questions
Does an immune signature retain its association with outcomes when tested in an independent cutaneous melanoma cohort?
- Study design
- External validation of a fixed signature, stratified by stage, sample site and treatment.
- What to measure
- Discrimination, calibration, documented response and survival at a prespecified horizon.
- Interpretation limits
- Cutaneous melanoma findings should not be extended to uveal or mucosal melanoma. Sampling bias may confound immune signals and tissue composition.
Interpretation limits
Cutaneous melanoma findings should not be extended to uveal or mucosal melanoma. Sampling bias may confound immune signals and tissue composition.
Original references
Continue exploring
Research questions
Educational content for framing research. Consult the original document, study population and methodology before interpreting a conclusion. Methodology